Juan Diaz-Cartelle Named Chief Medical Officer at Microbot Medical

Microbot Medical Inc. has appointed Juan Diaz-Cartelle, M.D., as its new chief medical officer (CMO). He succeeds Dr. Eyal Morag, who was based in Israel and played an integral part in developing and testing the LIBERTY Endovascular Robotic System from its inception phase. 

Diaz-Cartelle’s hiring coincides with the company’s transition from focusing mainly on research and development in Israel to its U.S.-based activities, which includes its planned clinical trials for the LIBERTY Endovascular Robotic Surgical System in the United States, the U.S. Food and Drug Administration (FDA) regulatory process, and establishing commercial foundations to enter the U.S market.

“We are fortunate to have Dr. Diaz-Cartelle join our team, especially with his extensive experience in the endovascular and interventional space. Dr. Diaz-Cartelle’s appointment is a testament to our commitment to excellence in our transition to the clinical and regulatory phase, especially as we are approaching our IDE submission and our upcoming clinical trial in the U.S.,” Microbot Medical Chairman/President/CEO Harel Gadot said. “His knowledge in clinical trial management, as well as leading medical affairs activities, will be invaluable as we work towards FDA clearance and continue to set new standards in robotic surgery.”
 
Diaz-Cartelle brings to Microbot a wealth of experience in the endovascular and interventional space, as well as a track record in clinical research. Before joining the company, he served for 14 years as senior medical director for the Peripheral Interventional Division (Endovascular and Interventional Oncology) at Boston Scientific Corporation. In this role, he played a pivotal part in developing global clinical strategy and study oversight, supporting commercial activities, and future pipeline development. Most recently he was the executive medical director at Haemonetics Corporation, where he advised the company on new investments in the cardiovascular space, among other responsibilities. Before joining the corporate life, he worked at NYU as a research scientist.
  
“I’m thrilled to join Microbot at this stage, as through my career, and especially over the past few years, I became a true believer in the role of robotics in the endovascular space,” Diaz-Cartelle stated. “I’m looking forward to being part of the team that supports the clinical trials and eventually the commercialization of the LIBERTY System, and to bring added value to physicians, patients and healthcare systems globally.”

The LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are used in endovascular procedures by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The company believes the LIBERTY Endovascular Robotic Surgical System’s remote operation can potentially be the first system to democratize endovascular interventional procedures.
 
Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the body’s natural and artificial lumens.